5 days in raltegravir and 53 days in darunavir/r
Las experiencias con estas FDCs en terapia dual siguen siendo limitadas
To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients
RADAR compared an NtRTI-sparing regimen of ritonavir boosted darunavir plus raltegravir with boosted darunavir plus tenofovir with emtricitabine
Design: Phase IIb, single-arm, open
What to Wear in Hilton Head in Spring (March, April, May) Springs at Hilton Head Island feel like a preview of summer, with warm temperatures already arriving in the area
Hilton Head Rentals offers vacation homes, condos, villas and other accommodations for visitors to Hilton Head Island, SC
Papyrus Belt Pale Sand
ING114915 Study Team Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Background: In January 2014, the European Medicines Agency issued a marketing authorization for dolutegravir (DTG), a second-generation integrase strand transfer inhibitor for HIV treatment
Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil
Objective: To explore darunavir /ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients
Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy
Methods: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir Todd T
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir All patients received raltegravir (one 400-mg tablet twice daily), etravirine (two 100-mg tablets twice daily), and darunavir plus low-dose ritonavir (two 300-mg darunavir tablets plus 100 mg ritonavir twice daily)
18 7 37 14 27 0 10 20 30 40 50 Overall <100,000 copies/mL ≥100,000 copies/mL) Baseline HIV RNA Level Darunavir/r + Raltegravir Darunavir/r + Tenofovir
Darunavir/ritonavir in combination with raltegravir was well tolerated in patients
27 The most common background regimens included darunavir/ritonavir/tenofovir disoproxil A Prospective Randomized trial on Abacavir/lamivudine plus DArunavir/ritonavir or Raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR Study) PLOS ONE
Abacavir, TDF, emtricitabine and lamivudine are all acceptable nRTI drugs for use in pregnancy